Diabetes

Important health screenings for patients taking antipsychotic medication are not being carried out in certain patient groups.

Patients who develop foot ulcers and necrosis as a result of their diabetes may be at risk of experiencing significant cognitive declination.

Potential risk of leg and foot amputations associated with the use of the diabetes medication canagliflozin.

Pharmacists can have a positive influence on medication adherence and several other factors in type 2 diabetes.

Diabetes drug interactions may decrease medication efficacy, increase toxicity, challenge adherence, and cause adverse events.

Patients with diabetes have a higher pill burden than the general population, so pharmacists should pay particular attention to potential drug interactions with antidiabetic agents.

Dendritic cell-based therapy shows promise treating diabetic peripheral neuropathy and ulcerations in the cornea and skin.

As melatonin levels rise, beta cells are prompted to release less insulin.

Diabetes in pregnant women may be associated with a lower supply of breast milk.

This article highlights several key therapeutics areas for insulin degludec that every pharmacist should know.

About 60% of patients with diabetes worldwide are Asian.

Pharmacists should double-check that patients with diabetes are vaccinated against hepatitis B, pneumococcal disease, and influenza.

Screening for vitamin D levels vital when treating adolescents with diabetes.

Incretin-based drugs help type 2 diabetes patients reduce blood sugar.

Incretin-based drugs help type 2 diabetes patients reduce blood sugar.

Pediatric diabetes and pediatric diabetic nephropathy rates significantly increase at age 12.

Combination treatment approach helps control diabetes and obesity.

Combination treatment approach helps control diabetes and obesity.

Pharmacist-led diabetes collaborative drug therapy management programs impact patients with type 2 diabetes.

Pharmacist-led collaborative care management programs for type 2 diabetes are associated with better glycemic control and lower health care costs compared with primary care settings that lack these programs.

A combination of blocking glucagon and insulin replacement therapy could normalize blood sugar levels.

Diabetes isn't the only therapeutic class that has seen substantial drug price hikes over the past decade.

Faulty protein kinases can lead to conditions such as diabetes, cancer, and cardiovascular disease.

Limited evidence has examined dual therapy in treatment-experienced diabetes patients.

Metformin and DPP-4 inhibitor dual therapy provides less durable glycemic control than the addition of sulfonylureas or TZD to metformin in diabetics.